News & Stories

See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.

DTx Pharma Video – Using siRNA to Treat Charcot-Marie-Tooth Disease Type 1A

May 7, 2023 | CMTRF Funded Research, Drug Development, Research News

Thomas F. Sander Joins CMT Research Foundation Board of Directors

Apr 27, 2023 | Press Releases

ATLANTA (April 26, 2023) CMT Research Foundation (CMTRF), a patient-led, non-profit focused on delivering treatments and cures for Charcot-Marie-Tooth disease, today announced that rare disease sales specialist, Thomas F. Sander, has joined its Board of Directors....

Edritz Javelosa to Join the CMT Research Foundation as Chief Scientific Officer

Apr 17, 2023 | Press Releases

ATLANTA (April 17, 2023) Edritz Javelosa (Hav-a-low-sa), PhD, who has been at the Muscular Dystrophy Association (MDA) since 2019 and Research Portfolio Director since 2021, has joined the CMT Research Foundation (CMTRF) as Chief Scientific Officer. Reporting to...

The CMT Research Foundation Appoints Anna Combes Vice President of Philanthropy

Apr 10, 2023 | Press Releases

ATLANTA (April 10, 2023) Anna Combes has joined the CMT Research Foundation in the newly-created position of Vice President of Philanthropy. Reporting to the Chief Operating Officer, Ms. Combes will be responsible for fundraising and development activities, including...

The CMT Research Foundation (CMTRF) Joins the European CMT Federation (ECMTF)

Mar 28, 2023 | News, Press Releases

The CMTRF is happy to announce that they are joining the ECMTF, a non-profit organization grouping European and worldwide national associations supporting people affected by the Charcot-Marie-Tooth (CMT) disease or neuromuscular disorders. One of the primary goals of...

Peter de Silva, Board Member of the CMT Research Foundation and Former Retail President of TD Ameritrade, Publishes Taking Stock

Mar 23, 2023 | Life with CMT, Press Releases

Taking Stock engagingly toggles back and forth between de Silva’s highly successful business career and his quiet battle with CMT ATLANTA (March 23, 2023) Peter de Silva, a nationally recognized and highly accomplished financial industry executive whose career...

CMT Research Foundation Invests in Vanderbilt University School of Medicine to Advance Research for CMT1A

Mar 13, 2023 | CMTRF Funded Research, Press Releases, Research News

ATLANTA (March 13, 2023) The CMT Research Foundation, a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease*, has invested in a project at Vanderbilt University School of Medicine Basic Sciences that seeks to treat the problem...

CMT Research Foundation Collaborates with Augustine Therapeutics on New Potential Therapy for Charcot-Marie-Tooth Disease

Mar 2, 2023 | CMTRF Funded Research, News, Press Releases, Research News

ATLANTA (March 2, 2023) The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT)*, is pleased to announce a collaboration with Augustine Therapeutics, a Belgian pharmaceutical company...

CMT Research Foundation and Nanite Inc. Announce Partnership to Enhance Therapeutic Efficacy of Antisense Oligonucleotides in CMT1A

Feb 22, 2023 | CMT Research Updates, CMTRF Funded Research, Press Releases, Research News

ATLANTA, GA (February 22, 2023) The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease*, today announced a partnership with Nanite, Inc., a Boston-based biotechnology company developing...

Continuation of Inflammation Research for CMT1B

Feb 14, 2023 | CMT Research Updates, CMTRF Funded Research, Research News

In 2020, the CMT Research Foundation had funded renowned nerve disease expert, Dr. Rudolf Martini of University Hospital Würzburg (Germany), to investigate whether inhibiting inflammation in the peripheral nerves could reduce symptoms and improve outcomes for patients...